摘要
目的研究培美曲塞与多西他赛在晚期非小细胞肺癌靶向治疗失败后挽救化疗中的应用效果。方法筛选2018年1月~2020年1月本院的60例晚期非小细胞肺癌靶向治疗失败后挽救化疗的患者作为研究对象,依据患者选择的药物种类分为观察组和对照组,每组各30例,对照组采用多西他赛治疗,观察组予以培美曲塞治疗,对比分析两组的近期治疗效果、生存质量评分和毒副反应发生情况。结果观察组病症控制率为66.67%,对照组病症控制率为36.67%,观察组病症控制效果更好;观察组生存质量评分为(65.2±3.4)分,对照组生存质量评分为(51.7±4.6)分,两组比较差异有统计学意义(t=12.926,P=0.000);观察组各项毒副反应发生率均低于对照组,差异有统计学意义(P<0.05)。结论在晚期非小细胞肺癌靶向治疗失败后进行挽救化疗中选用培美曲塞有更好的治疗效果,可以较好的进行临床治疗,改善患者的生活质量,且产生的毒副反应较少,在实际临床中的应用价值较高。
Objective To research the application efficacy of pemetrexed and docetaxel in salvage chemotherapy after failure of targeted therapy for advanced non-small cell lung cancer.Methods A total of 60 patients in salvage chemotherapy after failure of targeted therapy for advanced non-small cell lung cancer admitted to our hospital from January 2018 to January 2020 were selected as the research objects.According to the drug types selected by patients,and they were divided into the observation group(n=30)and the control group(n=30).The control group was treated with docetaxel,while the observation group was treated with pemetrexed.The short-term treatment efficacy,quality of life(QoL)score and toxic reaction of the two groups were compared and analyzed.Results The results of data analysis showed that the disease control rate of the observation group was 66.67%,while that of the control group was 36.67%,and the disease control efficacy of the observation group was better.The QoL score of the observation group was(65.2±3.4)points,while that of the control group was(51.7±4.6)points,and the difference was statistically significant(t=12.926,P=0.000).The incidence of toxic reaction in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The application of pemetrexed in salvage chemotherapy after the failure of targeted therapy for advanced non-small cell lung cancer has better therapeutic efficacy.It can be applied for better clinical treatment and improve the QoL of patients with fewer toxic reactions.Therefore,it has high practical application value in clinical practice.
作者
熊柳冰
XIONG Liubing(Affiliated Huidong Hospital of Guangdong Medical University,Huidong516300,China)
出处
《中国现代医生》
2020年第32期103-106,共4页
China Modern Doctor
关键词
培美曲塞
多西他赛
晚期非小细胞肺癌
靶向治疗失败
挽救化疗
Pemetrexed
Docetaxel
Advanced non-small cell lung cancer
The failure of targeted therapy
Salvage chemotherapy
